We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-13.68%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$179M
AUM Growth
-$34.5M
Cap. Flow
+$2.91M
Cap. Flow %
1.62%
Top 10 Hldgs %
60.25%
Holding
55
New
14
Increased
12
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$4.1M
2
DTIL icon
Precision BioSciences
DTIL
+$4.01M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$2.67M
4
UTHR icon
United Therapeutics
UTHR
+$2.64M
5
RZLT icon
Rezolute
RZLT
+$2.14M

Top Sells

Rank Stock Value
1
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$5.52M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$3.96M
3
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$2.47M
4
GHRS icon
GH Research
GHRS
+$2.29M
5
LONA
LeonaBio Inc
LONA
+$1.89M

Sector Composition

Rank Sector Weight
1 Healthcare 88.88%
2 Financials 7.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DICE
51
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-37,500
Closed -$717K
JNCE
52
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-813,500
Closed -$5.52M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Acuta Capital Partners held 55 positions worth $179M, down 16% from $214M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners's Q2 2022 filing shows 14 new, 12 increased, 10 reduced and 12 closed positions. Its largest new stake was Arcus Biosciences: 167,500 shares worth $4.24M. The largest sale was Jounce Therapeutics, Inc. Common Stock, an estimated $5.52M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier, followed by Financials.

  • Acuta Capital Partners's largest Q2 2022 buy was Arcus Biosciences: 167,500 shares worth $4.24M.
  • Acuta Capital Partners added most to Mirati Therapeutics, Inc. Common Stock in Q2 2022, an estimated $2.67M increase.
  • Acuta Capital Partners's biggest Q2 2022 reduction was GH Research, cutting an estimated $2.29M.
  • Acuta Capital Partners fully exited Jounce Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $5.52M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $179M portfolio in Q2 2022.
  • Acuta Capital Partners opened 14 new positions and closed 12 in Q2 2022.
  • Acuta Capital Partners's portfolio value fell 16% quarter-over-quarter to $179M.

Based on Acuta Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.